Omega backs Andrew Alliance’s series-B

The investment will enable Andrew Alliance to develop its co-worker robot Andrew, which is designed to assist scientists.

The company will also establish its commercial operations in the US market by opening an office in Boston. The Massachusetts Life Sciences Centre in Boston will house the new office. It also hosts the state's 10-year, $1bn Life Sciences Initiative.

Omega said it was impressed by the many uses for the Andrew pipetting robot in research, diagnostic and clinical laboratories across the life sciences industry. It also noted that the industry needs more precise, scalable operations, which cannot be achieved manually.

The healthcare-focused fund specialises in late stage life science investments and injected €2.5m into BioSilta, a Finnish developer of microbial growth systems and technology, in June this year.

Company
Founded in 2011 in Geneva, Andrew Alliance develops the Andrew robot, a co-worker robot designed to assist scientists in a routine laboratory operation called ‘liquid handling'. Andrew takes over the manipulation of commercial laboratory pipettes designed for manual operations, freeing up scientists for other work and minimising health risks and errors.

The robot is available in more than 17 countries through a network of distribution partners and is distributed directly by Andrew Alliance elsewhere.

People
Otello Stampacchia led the deal for Omega Funds. Piero Zucchelli is the CEO of Andrew Alliance. Vincent Ossipow is a venture partner at Omega and will join Zucchelli and Sam Eletr, co-founder of Andrew Alliance, on the board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Expansion
• Technology
• Switzerland